Company intelligence / Profile preview
Matisse Pharmaceuticals
Geleen, Netherlandsmatissepharmaceuticals.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Matisse Pharmaceuticals is developing M6229, a low-anticoagulant fraction of heparin that neutralizes toxic extracellular histones implicated in sepsis and septic shock. Preclinical studies have shown efficacy in animal models, and the drug is currently in phase 1/2a clinical development. The company recently completed a financing round to support a large-scale phase II trial and scale-up for commercial production. GMP manufacturing capabilities are operational for their lead compound.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecule (specifically, a non-anticoagulant heparin fraction)Biologic (heparin derivative)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No specific major pharmaceutical or biotech partnerships publicly disclosed; the company has built a network of strategic partners and investors.
Beyond the preview
Go deeper on Matisse Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Matisse Pharmaceuticals.